0
Deep & Emerging Tech·October 23, 2026·1 min read

AI chipmaker Cambricon’s sales miss points to tight chip supply in China

Share

Cambricon doubling revenue to 3.53B yuan yet missing a 6.26B forecast underscores that China’s AI chip growth is now gated by HBM and advanced fab access, not demand. If you operate in or sell into China, plan for persistent supply volatility and consider architectures that can flex across multiple accelerator vendors.

Deep & Emerging Tech

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

For oncology operators, the question isn’t just whether Moderna’s cancer vaccine can match Keytruda in the short term—it’s whether it can durably suppress recurrence over years, which changes trial design, follow-up infrastructure, and payer negotiations. Early data will drive headlines, but long-term outcomes will drive formulary and care-pathway rewrites.